BLOG

Sign up for the V2V Insight Newsletter!

Have you checked out our newsletter?

Stay ahead with expert insights, strategic tips, and industry trends—all designed to boost your brand's med comm initiatives.

"*" indicates required fields

Name*

Get fresh insights and candid perspectives on timely issues impacting the pharmaceutical industry from our blog. 

The Latest News

Will Your Launch Strategy Succeed or Fail?

The Challenge: A Faster, More Complex Launch Environment In today’s pharmaceutical market, strong science is the foundation, but it doesn’t always guarantee a successful launch. Many of us have experienced a disappointing launch when everything we anticipated pointed to success. Today, launches are more complex than they were a decade

READ MORE »
Magnifying glass identifying an expert

How to Identify Top Experts

Discover proven strategies for selecting the right engagement tools for pharmaceutical Virtual Speaker Programs to create memorable peer-to-peer learning experiences that drive results.

READ MORE »
GLP-1 Administration

BioPharma Trends in the News – September 2025

The BioPharma industry is in rapid flux, shaped by rising tariffs, shifting policies, and new barriers to prescription access. Here’s a quick look at the forces driving change. Source: Time.com The time is now to review your campaigns as FDA oversight ramps up after years of minimal enforcement. Trump’s executive

READ MORE »
Health Insurance Form

BioPharma Trends in the News – August 2025

Source: FiercePharma President Donald Trump is pressing ahead with plans to impose steep tariffs on imported pharmaceuticals—starting small but ramping up to 250%—in a bid to push drug manufacturing back to the U.S. The move, paired with a revived “most favored nation” pricing policy, has already spurred major pharma companies

READ MORE »
Microphones surrounding a TV

BioPharma Trends in the News – July 2025

Source: PharmaVoice A new bill led by two independent senators seeks to ban direct-to-consumer (DTC) pharmaceutical advertising, arguing that promotions drive up drug costs and mislead patients. While some support the move as a step toward transparency, critics claim it could limit patient awareness and hinder innovation in healthcare marketing.

READ MORE »